Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
about
Advances in the management of acute retinal necrosisNovel agents and strategies to treat herpes simplex virus infections.Agents and strategies in development for improved management of herpes simplex virus infection and disease.The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.Efficacy of Oral Valacyclovir Treatment in a Case with Acute Retinal NecrosisClinical management of selected oral fungal and viral infections during HIV-disease.Emerging drugs for varicella-zoster virus infections.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementValacyclovir in the treatment of acute retinal necrosis.Varicella-zoster virus (chickenpox) infection in pregnancyAcyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.Case files of the Harvard medical toxicology fellowship: valacyclovir neurotoxicity and unintentional overdose.Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation.Novel drug delivery approaches on antiviral and antiretroviral agents.2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosidesGlycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeuticsAntiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses.Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.Oral complications in the treatment of cancer patients.Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention.Using predrugs to optimize drug candidates.Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents.Prevention of herpes zoster pain.FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial.MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.Amino acid esters substituted phosphorylated emtricitabine and didanosine derivatives as antiviral and anticancer agents.Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues.Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.Medical management approach to infectious keratitis.Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.Pharmacokinetics of a single oral dose of acyclovir and valacyclovir in North American box turtles (Terrapene sp.).Development of mannosylated liposomes for bioadhesive oral drug delivery via M cells of Peyer's patches.Calculation procedures and HPLC method for analysis of the lipophilicity of acyclovir esters.A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.In search for effective and definitive treatment of herpes simplex virus type 1 (HSV-1) infectionsVolatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections
P2860
Q28080841-5C864174-5019-4F1B-BD79-A6670296B0B2Q30332444-2BD13D84-5802-4A98-A9BF-14637736A676Q30350341-87DAA2BC-7765-408A-ADF2-A86CA07525E0Q33611436-F23AF852-D002-4AB4-B8BD-BF846C6C27C4Q33790485-56B5AE04-1F5A-4890-B307-02B3C24C46ACQ33945706-B6C1746D-E6AF-4C9B-8E84-66F448F1300DQ34027426-D64BF6D1-4A8F-4B26-A911-302D82E94CFFQ34149904-75785464-0C05-40DE-8DFA-E27460160885Q34403015-C4C959D8-9D54-45C3-84DF-B01BE55FB776Q35162932-830CEEAC-30DF-4BF8-8EC3-364FA7F062B8Q35166138-ED63AD80-E135-489A-8B90-1A522313D0D5Q35210113-97A26CDD-DC1A-413A-925E-E5A996B268E5Q35668187-7D90F06F-DC7B-4B6A-9338-89E17C765B5FQ36283306-D4325A19-E1E4-4D7A-B746-E47F31EEA46FQ36364125-6AEE5FFA-655F-4C38-B23D-E07C5F0D0201Q36433206-290056D0-90EE-4B89-8D25-E46DEBC60E0CQ36866689-9D9DBF96-64FC-4F3F-A9AB-93646C2281CCQ37252268-3DE2C4A4-F555-4617-AF5A-9B26E20DFB75Q37694574-17DBAEE5-73F2-40A6-89AD-437E82CFAC99Q37838501-BE8F3EA4-4D6A-4CFD-9E98-3333E1DFB506Q38049148-23E8D1BD-C10A-49D7-982B-93954DD6BD43Q38243993-3C922FE7-737A-4F6B-830F-0C202CDA5BB4Q38858400-CE106273-2CAD-4454-93AB-387376DE22F2Q39254009-DD0AAA67-2349-4416-A80B-FCECCB986B96Q40429173-0C6B9786-A50D-4771-936C-835C095AE4EBQ41324351-6752C603-B1E7-4C08-A1D6-BE03CD5EC54BQ42220956-0C97F631-77CD-46FE-8EE0-339D5D379B2BQ42537090-89489D52-7D29-4D74-862C-4B763E26DC05Q42621014-A7192345-246C-42D9-BA7C-5AFF79575342Q43187227-E082EC59-0C8B-4222-B0A5-609C954ECA44Q44351368-6DBC742D-B8BA-4B97-A07E-3B4350D80A89Q44800838-4625BC08-6BEA-4970-9B47-3DB2BC8506E9Q45963439-398D1C6B-A9A5-443D-9A2E-A56447008741Q51107083-AB8942FF-7AE5-4283-B83A-08EB4B4221C8Q53327420-3EA0984F-4BF9-45B7-BE71-7A6802687370Q56789970-1D46DD5D-765F-40FB-AB15-64F6C927A8CDQ57821292-A270F689-5F97-4909-B0DE-4A1286E58526
P2860
Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@ast
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@en
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@nl
type
label
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@ast
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@en
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@nl
prefLabel
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@ast
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@en
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@nl
P1433
P1476
Valacyclovir: a review of its ...... erties, and clinical efficacy.
@en
P2093
Beutner KR
P304
P356
10.1016/0166-3542(95)00066-6
P577
1995-12-01T00:00:00Z